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The Argus II Retinal Prosthesis 
System
Edward Bloch and Lyndon da Cruz
Abstract
The field of retinal prosthetics has seen significant advances in the past 3 
decades. Encouraging results from different groups have shown coarse objective 
functional improvement, using a range of technological and surgical approaches. 
The Argus II retinal prosthesis system was the first of its kind to receive regula-
tory approval for commercial use in Europe and the USA. The device is designed 
to replicate the function of photoreceptors in converting visual information into 
electrical neural signals in patients with profound visual loss secondary to degen-
erative retinal disease. Results from a phase II study of 30 patients have demon-
strated improved performance in basic tests of visual function, object recognition, 
letter reading, prehension, orientation and mobility tasks. It is now the most widely 
implanted retinal prosthetic device worldwide. This chapter provides an overview 
of the requirements of a retinal prosthetic system, the results from the Argus II 
device to date, and an insight into some of the challenges and future directions of 
visually restorative therapies.
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1. Introduction
Retinal diseases, including both inherited and acquired conditions, are a major 
cause of blindness. In 2010, the WHO estimated that 285 million people in the world 
were visually impaired from all causes [1]. Hereditary retinal disease represents 
another significant contributor to unavoidable worldwide blindness, with condi-
tions such as retinitis pigmentosa (RP) affecting an estimated 1/4000 people, or 
0.025% of the population, often of working age [2]. Representing a heterogenous 
group of inherited diseases, RP affects the rod and cone photoreceptors (PRs), 
causing progressive, profound visual impairment, but with relative preservation of 
the inner retinal architecture [3]. This anatomical region consists of retinal ganglion 
cells (RGCs) and their nerve axons, which transmit visual information to the brain, 
along with other regulatory interneurons, such as bipolar, amacrine and horizontal 
cells, and Müller support cells (Figure 1). Preservation of these structures and 
the associated retinotopic map has led to RP becoming a model for many forms of 
visual restorative therapy, in particular, retinal prosthetics.
Another significant retinal cause of blindness is age-related macular degenera-
tion (AMD), accounting for 5% globally [1]. It has been projected that, by 2040, 
this condition alone will affect 288 million people, 3.25% of the predicted global 
population [4, 5]. Late AMD comprises geographic atrophy (dry) and neovascular 
(wet) AMD, and is a significant cause of morbidity in the western world, with a 
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prevalence of 2.4% in the UK [6, 7]. While anti-VEGF treatment has revolutionized 
the treatment of wet AMD, there is currently no treatment for the dry subtype, 
which results in degeneration of the PR layer and impairment of central vision in 
1.3% of the UK population [7].
The concept of retinal prosthetics is centred on the phenomenon of electrically 
induced subjective visual percepts or ‘phosphenes’. These phosphenes have been 
elicited by applying electrical currents across the ocular surface since as long ago as 
the eighteenth century. In the early twentieth century, Förster demonstrated that 
phosphenes could be elicited in blind patients via direct stimulation of the visual 
cortex, leading, in 1968, to the first chronic implantation of an intracranial visual 
prosthesis [8, 9]. In the 1980s, advances in microfabrication, materials engineering 
and retinal surgery provided a fecund environment for emergence of the field of 
retinal prosthetics—devices that could deliver direct stimulation to the residual 
retinal neurons.
2. Principles of natural vision
In order to create a retinal prosthesis, it is necessary to account for the processes 
that take place within the human eye, where light is absorbed, converted to an 
electrical impulse and encoded into a neural signal. Physiological capture of the 
visual scene occurs via the natural optical system, comprising the cornea, iris and 
crystalline lens, which focus light onto the photosensitive retinal cells. Within the 
photosensitive rods and cones, a photochemical reaction leads to transduction of 
light into a graded electrical neural signal with eventual RGC stimulation. The 
axons of the RGCs constitute the optic nerve. In the native retina, a significant 
amount of information compression occurs at the level the PRs, the interneurons 
and the RGCs, from where it is encoded for transmission via the optic nerve to the 
midbrain and cortical visual pathways.
There are two types of PR, rod and cone cells, which number ~120 and 6 million 
respectively in each eye, resulting in an average input of 100 photoreceptors to each 
of 1.5 million RGCs [10, 11]. Rods are sensitive to low levels of light and are most 
Figure 1. 
A schematic demonstrating the anatomy of the eye and organization of the retina. RNFL: retinal nerve fibre 
layer; RGCs: retinal ganglion cells; RPE: retinal pigment epithelium.
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populous at about 20° eccentricity. The cone cells are responsible for colour vision 
and function best in bright light. They are most densely concentrated in the foveal 
region where they are in almost 1:1 ratio with RGCs, beyond which they decline 
considerably in density [12].
Following the transduction of photic energy into electrical impulses, bipolar 
cells effectively transmit the information from PRs to RGCs, but may have an 
excitatory (ON) or inhibitory (OFF) response to hyperpolarisation and are also 
influenced by the actions of horizontal and amacrine cells, which can introduce lat-
eral inhibition of signals. Each RGC has a centre-surround receptive field organiza-
tion and its stimulation pattern will depend both on the size of its receptive field, 
the input stimulation frequency, and whether it is an ‘on-centre’ or ‘off-centre’ 
cell. Furthermore, RGCs are not functionally homogeneous, with certain cell 
populations specialized in particular functions and projecting to specific midbrain 
regions. Most of the 1 million nerve axons of the RGCs pass via the optic nerve to 
their respective lateral geniculate nucleus (LGN), located within the thalamus. The 
LGN is a layered structure and each part receives axons from specific ganglion cell 
types. A degree of visual processing is thought to occur at this point, before pro-
jecting on towards the primary visual cortex, where all higher cognitive processing 
takes place [12].
The processing power of the retina enables us to resolve detail with remark-
ably high spatial and temporal resolution, across a broad spectrum of contrast and 
colour. Beyond this, higher neuro-cortical integration allows us to process and 
recognize objects, words and faces, appreciate distance, orientation and movement, 
while coordinating our visual interpretations with other sensory inputs and motor 
outputs. Together this information allows us to decide what is safe or dangerous, 
fast or slow, attractive or repulsive. All this activity occurs in milliseconds, with 
a seemingly infinite refresh rate. This phenomenon is reliant on a very complex 
system that can rapidly capture, assimilate, compress and process an enormous 
amount of visual information.
Clearly, creating a micro-electronic system, which can come close to replicating 
the processing capacity of the human visual system, is currently an unrealistic goal. 
Instead, we must focus on how visual processing software and hardware engineer-
ing can be combined to produce a device that can resolve the minimum interpreta-
ble visual information such as to be beneficial to patients with profound vision loss.
Simulated prosthetic vision (SPV) studies have been undertaken to try and 
estimate the optimum spatiotemporal image processing techniques for specific 
task completion, as well as the basic hardware requirements to best deliver RGC 
stimulation patterns [13–17]. SPV studies have extensively investigated the spatial 
resolution, visual field and contrast required for assorted activities of daily living, 
concluding that a minimum resolution of ~600–1000 pixels over a visual field 
15° × 15° can permit reasonable accuracy in manipulation, recognition, orientation 
and mobility tasks. The resolution of around 3 pixels/degree2 is similar to that in 
some currently available photovoltaic retinal prosthetic systems while fields of at 
least 15° × 15° have been created. However, and disappointingly, there remains a 
mismatch in the functional aptitude demonstrated by subjects in SPV studies and 
that in recipients of visual prostheses. This suggests that other factors, such as the 
effects of behavioural adaptation, perceptual learning and cortical plasticity, as well 
as the loss of the intrinsic retinal processing capacity, could be critical requisites 
in the development of a visual restorative system that could deliver appreciable 
functional value [18, 19].
One of the advantages of a retinal prosthesis is that, by placing a device at the 
most distal part of a non-functioning visual system, it is possible to benefit from 
any residual downstream neuronal organization within the retina and visual 
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pathways. However this theory relies on the assumption that the proximal visual 
system remains intact. It has been demonstrated that outer retinal degenerative 
disease results in a cascade of reorganization and remodelling within the retina and 
central nervous system, even taking place before there is clinical evidence of PR loss 
[20–24]. A stepwise deterioration culminates in extensive neuronal cell migration, 
rewiring and death, accompanied by glial hypertrophy and retinal remodelling, 
rendering the retina incapable of processing or encoding visual data. This neuronal 
plasticity carries implications for all forms of visually restorative therapy, but 
particularly for prostheses, which are currently introduced at a late stage of visual 
impairment, where there has already been widespread reorganization with limited 
scope for rescuing vision. However, it may be that future iterations of bionic devices 
could even be introduced earlier in the disease process in an attempt to halt or 
reverse the remodelling process.
Another matter that remains unclear is the extent to which the human brain 
undergoes reorganization following loss of visual sensory input. Both animal and 
human studies have shown that there is the capacity for neuroplasticity as a func-
tional adaptation to loss of a sensory modality [25–27]. For example, visual cortical 
activity has been demonstrated in blind subjects while reading Braille [28, 29].  
Other studies of patients undergoing cochlear implant surgery, have shown cor-
relation between the pre-operative auditory organization and activation and 
subsequent success of the neuroprosthesis [30, 31]. If a method could be developed 
by which a patient could be assessed for the feasibility of generating interpretable 
phosphenes, this would enhance patient selection and thus outcomes in this area 
of visual restoration. Further understanding of the nature of cortical plasticity in 
sensory loss and how subjects can adapt to a new form of vision with perceptual 
learning and rehabilitation, is sure to enhance the beneficial effect of visual restor-
ative treatments in the future.
3. Principles of prosthetic vision
In order to simulate the complex series of events that take place between the 
outside world and the visual cortex, a prosthesis system needs to perform a specific 
sequence of actions, namely image capture, processing of the image, delivery of 
both image data and signal amplification to the microelectrode array, which in turn 
must deliver a suitable stimulation current (directly or indirectly) to the RGCs. 
All this must take place with a biocompatible system that can produce adequate 
stimulation currents without causing degradation to itself or to the target tissue. 
Furthermore, the device needs to be straightforward to implant, modify or explant, 
while remaining portable, discreet and fashionable.
3.1 Image capture
Presently, there are two principal means of ‘image capture’ that have found 
some success in retinal prosthetic systems. The first is to capture information 
from the visual scene using an external video camera, which is usually glasses-
mounted. The video camera then transmits data directly to an external video-
processing unit (VPU). The advantage of this approach is not only that it is 
technically simpler, but also it avoids any impediments to collecting high quality 
information about the visual scene, thus facilitating any downstream image pro-
cessing. However, due to the fixed camera position, there is a risk of discrepancy 
between its orientation and that of the eye, risking inaccuracies in the perceived 
spatial location of an object of interest following retinal stimulation. Proposed 
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solutions to this problem include both the incorporation of an eye tracker to 
coordinate the direction of gaze with the stimulation pattern, or placement of 
the camera system intraocularly, for which there have been some preliminary 
attempts to design such a system [32].
The second image capture system that has shown promise is the photodiode 
array device. First developed by the Chow brothers as the artificial silicon retina 
(ASR), this comprises a passive microphotodiode array, which was intended to 
intrinsically transform ambient light that falls on it into an electrical current 
capable of stimulating retinal neurons. The ASR array consists of 5000 inter-
connected photodiode anodes with individual isolated cathodes, each with an 
iridium oxide electrode. This method was advantageous in as far as it allowed a 
large number of pixels to be stimulated simultaneously, it was wireless and also 
it allowed for precise coordination between the eye position and the projected 
visual scene [33, 34]. However, in its first iteration, it was unable to deliver suf-
ficient stimulation current to deliver functional results and the parent company, 
Optobionics, has since closed down. Despite this initial failure, the concept of 
the photovoltaic array has been taken up and developed by other groups, with 
encouraging results. The Retina Implant AG group developed the Alpha IMS 
device that contains 1500 independent and autonomous photodiode-amplifier-
electrode units. The ambient light creates the stimulation pattern and an external 
power source amplifies the electrical signal [35, 36]. The ‘PRIMA’ Photovoltaic 
Retinal Implant system (Pixium Vision S.A.) combines aspects of both forms of 
image capture, in that is uses an external camera to capture the visual informa-
tion before processing and then transmitting the data as pulsed near-infrared 
light patterns from a specialized visual interface in a pair of glasses directly onto a 
subretinal photovoltaic array [37, 38].
3.2 Image processing
In some systems, the image processing takes place within an external analyser, 
which receives a high-quality signal from a camera system and transforms the data 
into a set of commands to be wirelessly transmitted to the microelectrode array to 
generate a specific stimulation pattern. In systems such as the Argus II retinal pros-
thesis, there are only 60 microelectrodes, meaning that even with perfect electrode 
contact and accurate retinotopic phosphene perception, the image resolution would 
still be low. As such, there is an emphasis on developing software algorithms that 
can filter the most relevant parts of a visual scene, before creating simple stimula-
tion configurations that map the object of interest onto the array. This process is 
known as saliency mapping, and similar algorithmic methods of rapid recognition 
and segmentation of information have previously been used with success in the 
form of speech processors for cochlear implants [39–42].
Simulation studies have shown that by applying transformations, such as edge 
detection, greyscale histogram equalization, intensity and contrast enhancement, 
task performance using a low resolution viewing system can be improved (Figure 2). 
Similarly, software has been developed to allow magnification of areas of interest in the 
visual scene, or even projection of a simulated object or face onto the array, in response 
to detection of the respective entity in the captured environment [43, 44]. The intel-
ligent retinal implant system (IRIS) II (Pixium Vision S.A.) has a ‘neuromorphic image 
sensor’, which is designed to capture the coordinates and intensities of changing pixels, 
the information from which can be encoded and divided into transient and sustained 
components. This can be used to direct image processing towards the most relevant 
parts of the visual scene, i.e. moving people or vehicles, while removing redundant 
excess visual information [45].
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All these types of pre-processing are relevant for devices that do not have 
intrinsic photosensitivity, but instead rely on external image capture systems. In the 
case of the photovoltaic systems, there is a greater spatial resolution due to the high 
density of photodiode-amplifier-electrode units, each of which acts as an indepen-
dent pixel. In theory, this enables greater intrinsic processing through more local-
ized neuronal stimulation and may also incorporate some downstream processing 
from the residual retina to select and transmit the most salient visual information to 
the brain [46, 47].
3.3 Data and power transmission
Delivery of encoded visual information and power to the microelectrode array 
is generally either wireless (via inductively coupled coils) or directly onto the 
microphotodiode array via the natural optical system of the eye. In variations of the 
former approach, there are several considerations that need to be made. Inductive 
coil systems function through radio-frequency telemetry, whereby an AC current 
passing through the external coil induces an AC voltage in the internal coil, which can 
be subsequently be converted into DC power. A capacitor in series with the secondary 
coil permits amplification of the received voltage by creating a tuned resonance at the 
transmitter frequency, thus supporting efficient power transfer while minimizing 
the body’s exposure to radiation. Although the data may be encoded onto the same 
signal as the power, it is more commonly accomplished with greater effect by using 
a separate, high frequency coil. The capacity for data and power transfer using this 
model is sufficient to support the resolution and refresh rate of current systems [48].
Location is an important consideration for an efficient inductive coil system. 
Many systems utilize a coil system that is similar to that of cochlear implants, with 
an electronics unit fixed to the bone postauricularly, which communicates with the 
retinal array via a tunnelled connecting wire. This approach was initially chosen 
due to the surgical familiarity to otolaryngologists and it allows for good coil 
contact for coupling. However, due to the prolonged duration of surgery, complex 
fabrication challenges and apparent reduction in system longevity, some systems 
have since been modified to incorporate a glasses-mounted transmitting coil which 
transmits to an implanted subconjunctival receiving coil, which is connected to 
the array via a sclerotomy. Another approach, as used in the EPI-RET3 implant, 
involves positioning a receiver coil into the lens capsular bag (following removal 
of the native lens). This approach still relies on an inductive power and data link, 
but negates the need for a transscleral wire, which carries a risk of infection and 
erosion. In addition, this system has a bi-directional enhancement system, which 
allows for simultaneous stimulation of and recording from the microelectrodes. 
Feedback from the system enables modification of the stimulation algorithms and 
patterns to accommodate any residual excitatory and inhibitory signal processing 
of the retinal neurons [49, 50].
Figure 2. 
An example of image processing transformations: the image of the bicycle first undergoes edge detection and 
is converted to greyscale. This is then transformed by circular binarisation into a black-and-white pixelated 
format. Finally the image is inverted, with the addition of four greyscale levels.
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3.4 Microelectrode array stimulation
There are several considerations when designing an electrode array to deliver 
electrical currents to the RGCs in order to replicate the spatial resolution (SR) of the 
natural retina. These include the electrode material, size, shape, spacing (pitch), 
tissue contact and the anatomical position of the array.
There are three primary sites for placement of a retinal stimulating microelec-
trode array (Figure 1): epiretinally (i.e. on the surface of the neurosensory retina), 
subretinally (i.e. between the retinal pigment epithelium and the degenerated 
outer retina) or suprachoroidally (i.e. between the sclera and the choroid). The 
advantage of the epiretinal placement is that the surgical approach is more familiar 
to vitreoretinal surgeons, allowing safer and easier implantation, adjustment and 
removal of devices. Furthermore, the interface with the vitreous cavity seems to 
permit safer heat dispersion. This set-up may be disadvantageous due to the fact 
that, in order to stimulate the RGCs, the stimulating current must pass through the 
retinal nerve fibre layer, which may produce ectopic visual percepts elsewhere in 
the retinotopic map.
In terms of a subretinal system, one proposed advantage is that by mimicking 
the position of the PRs in the natural retina, some of the stimulating current will 
pass via the residual bipolar system, exploiting graded response of the inner retinal 
neurons and thus the natural processing power of the retina. Moreover, it is felt 
that better electrode-tissue contact will be achieved with the subretinal than with 
the epiretinal approach. However, it has been noted that, due to underlying degen-
erative changes, surgical implantation can be difficult, and the longevity of these 
devices can be more limited [51].
Finally, suprachoroidal devices require a less invasive surgical procedure, which 
lends itself to easier repair or removal, but trials to date have been complicated by 
subchoroidal haemorrhage and fibrosis [52]. Due to the distance from the RGCs, 
these systems tend to require higher stimulation thresholds, leading to greater 
current dispersion and lowering the achievable SR. Overall, it seems that epiretinal 
and subretinal approaches have a superior performance in safety and efficacy to 
suprachoroidal implants. However, with pros and cons to both approaches, there is 
currently no clear evidence to suggest that, of these latter two, one system offers an 
overall advantage.
The challenge of electrode size and density is primarily a biological one, in as 
far as the native PR cells change in type, size, density and downstream signalling 
depending on their role and location in the retina. For example, cone PRs are, on 
average 6 μm in diameter, but in the centre of the fovea, they are around 1.5 μm in 
diameter and densely packed to permit the high resolution of vision that humans 
usually enjoy [53]. If we consider that normal vision is 20/20, meaning that the 
minimal angle of resolution at the retina is 1 arcminute, or the spatial frequency 
(SF) is 60 cycles per degree (cpd), then the SF required to achieve 20/200 (the 
approximate level of visual impairment) is 6 cpd. Since each degree angle sub-
tended at the human retina is represented by ~280 μm, a SF of 6 cpd would neces-
sitate a maximum pixel size of about 50 μm and, in turn an electrode size and pitch 
of 25 μm [54, 55]. Therefore, before factors such as electrode contact, dissipation 
of electrical current or heat are even considered, there is a significant theoretical 
constraint on the scale of manufacturing required to achieve a resolution corre-
sponding to a visual acuity of 20/200.
Among the smallest electrodes that have undergone human implantation to date 
are those of the alpha IMS, which are ~50 μm in diameter, with a 70 μm spacing, 
giving a theoretical maximum VA of about 20/250 [36]. Results have been reported 
of a grating VA of 3.3 cpd and optotype recognition acuity of 20/546 using this 
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device [56]. The Argus II device has 200 μm electrodes separated by 525 μm, which 
suggests a theoretical maximum VA of 20/1600. The best result, with grating acuity, 
has been reported as 20/1262 (just over 1 cpd) with this system [57].
Electrode shape is a factor that may significantly affect the integration of the 
device by creating an environment where retinal tissue can migrate around the 
array and create a close interface. Arrays have been designed with sunken chambers 
or ‘wells’, into which the inner nuclear layer cells have been shown to migrate. 
Another approach is the three-dimensional pillar array, with protruding electrodes, 
designed to produce an intimate apposition between the array and the neuronal cell 
bodies without requiring excessive remodelling of the retina [58].
Size, shape and contact of the electrode at the tissue interface are all important 
considerations to improve SR, but also have implications to the charge density per 
unit area. As the electrode size becomes smaller, there is an exponential increase 
in concentration of the current, which can result in target tissue damage [59]. 
Therefore there is an onus on finding materials that can permit the charge-injec-
tion requirements of neural stimulation, while minimizing conduction of heat 
or inducing tissue degradation. In addition to this, they must be biocompatible, 
waterproof and remain operational over an extended lifespan. While the precise 
electrochemical properties of the electrode-electrolyte interface, the capacitance 
and charge injection limits of different electrode materials is beyond the scope 
of this chapter, it is worth noting that new technologies, such as nanocoating, 
nanotubes and conductive polymers are providing promising developments in 
electrode fabrication, which may offer significant advantages over the more 
traditional metallic designs, such as iridium, platinum or titanium-based elec-
trodes [60–62]. The emerging field of tissue electronics, which is focused on the 
use of organic conductive and semi-conductive polymer alternatives to inorganic 
electronic systems, is rapidly advancing. Recently, long-term in vivo studies of a 
fully organic multi-layer device in rats have shown success in recovery of subcorti-
cal and cortical light responses, as well as improvements in visual behaviour  
[63, 64]. While current electrode devices achieve RGC stimulation by direct cur-
rent injection to trigger action potentials, it appears that organic coupling occurs 
in a more physiological manner by modulating local neuronal neurotransmitter 
release through discretely varying the membrane potentials [65]. It is probable 
that approaches using conductive polymers, or other chemical photoswitches  
(e.g. photochromic molecules or photoactive nanoparticles) permit a more natural 
interaction with the residual neuronal environment, which, in theory, could 
achieve cellular resolution.
4. Argus II retinal prosthesis system
The Argus II epiretinal device (Second Sight Medical Products Inc.) was the first 
retinal prosthetic system to obtain CE marking (2011) and FDA approval (2013) 
for commercial use, and is the most widely implanted retinal prosthetic worldwide. 
Comprising external and implantable components, it utilizes camera-based image 
capture and VPU processing, with wireless data and power induction, transmitting 
stimulation commands to an epiretinally located microelectrode array (Figure 3).
The Argus II system is implanted using standard pars plana vitrectomy and 
scleral buckling procedures, and usually the surgery includes removal of the native 
lens. Following removal of the vitreous and posterior hyaloid face, a conjunctival 
peritomy is performed and the recti muscles are isolated to allow fixation of an 
encircling band containing the internal coil and in-built application-specific inte-
grated circuit. A 5 mm sclerotomy is created for insertion of the 60-microelectrode 
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array and the connecting cable. This lies flush on the epiretinal surface and is 
secured in place using a spring-loaded titanium tack (Figure 4). A scleral allograft 
(or similar alternative) covers the hermetically-sealed coil and electronics case, 
which is then re-covered by Tenon’s capsule and conjunctiva, such that the internal 
components are invisible to the casual observer. To use the device, the external 
components are worn, including a glasses-mounted camera and external coil, and a 
portable VPU and power unit [57].
4.1 Development history
Throughout the 1990s, Humayun demonstrated that low current stimulation 
of dissected animal retinal tissue could produce localized retinal responses [66]. 
This was followed by acute epiretinal stimulation experiments of blind human 
volunteers, with various forms of retinal degeneration. It was shown that stimula-
tion could elicit subjective phosphenes, which in many cases could be accurately 
Figure 3. 
The components of the Argus II retinal prosthesis system (adapted with permission from Second Sight Medical 
Products).
Figure 4. 
Fundus photograph demonstrating an Argus II microelectrode array in situ.
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localized and resolved to an equivalent acuity of up to 4/200 [67, 68]. In a subse-
quent series of acute stimulation tests using multielectrode arrays, two patients 
were able to identify crude forms from discrete patterns of electrical stimulation, 
using 400 μm electrodes arranged in 3 × 3 or 5 × 5 grids.
These promising results led to the development of the Argus I epiretinal pros-
thesis, which was the first device to undergo chronic testing in 2002 in six patients 
with end-stage RP. The Argus I device included a 4 × 4 array, comprising 16 alter-
nating 250 and 500 μm diameter electrodes. The initial device design was based 
closely on that of cochlear implants, with an electronic unit surgically positioned in 
a postauricular recess of the temporal bone, from where a connecting cable would 
be passed along a groove in the bone and communicate with the intraocularly placed 
array. The external camera and VPU components captured the images, which, once 
encoded, were wirelessly transmitted via an antenna, that was magnetically held in 
position over the internal electronic unit. Results showed coarse functional perfor-
mance was better than chance with the device on, with one patient able to detect 
light, motion and simple shapes [69–71]. In another subject, it was recently shown 
that the device continued to elicit phosphenes sufficient to permit target localiza-
tion, orientation and mobility performance better than chance with the device 
on, 10 years postimplantation [72]. The overall safety and longevity of the device, 
which demonstrated coarse functional outcomes at a safe charge density limit, led 
to the development of the Argus II system, with a 6 × 10 microelectrode array and 
an optimized surgical approach.
4.2 Argus II results
The phase II multicenter clinical trial for the Argus II retinal prosthesis system 
began in 2006, enrolling 28 patients with end-stage RP, one with Leber congenital 
amaurosis and one with choroideremia. The primary endpoints of this study were 
safety and visual function, while secondary assessments of functionality included 
activities of daily living, such as orientation and mobility [57, 73, 74].
4.3 Safety outcomes
Witinn 12 months of the start of the trial, there were 18 reported serious adverse 
events (SAEs) requiring intervention, occurring in 10 of the 30 implanted patients. 
These included three cases of presumed endophthalmitis, three cases of conjuncti-
val dehiscence, three cases of conjunctival erosion, two cases of hyptony, two arrays 
requiring re-tacking and one case each of rhegmatogenous retinal detachment, 
tractional retinal detachment, a retinal tear, corneal opacification and an inflamma-
tory uveitis. The majority of these SAEs (78%) took place within the first 6 months 
after implantation and they were clustered among the initial 15 patients (72%). The 
reduction in SAEs in the second half of the trial was ascribed to refinement of both 
the device and the implantation procedure during the study, such as inclusion of 
prophylactic intravitreal antibiotics to the surgical protocol. All SAEs were success-
fully treated; in the cases of hypotony, the subjects required silicone oil tamponade 
(in one case for retinal detachment), which led to stabilization of the intraocular 
pressure [57, 73].
At 36 months, there were five additional reported late SAEs, including two 
further cases of hypotony and one each of infective keratitis, corneal melt and 
conjunctival erosion. Within this period, only one device required explantation, 
due to recurrent conjunctival erosion, and no eyes were enucleated [73]. At 5 years, 
the latest reported time point, there was only one additional SAE, which was a 
successfully treated retinal detachment, resulting in a total rate of 24 reported 
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SAEs among 12 (40%) of subjects. A total of three devices have been partially or 
completely removed at the request of the subjects, while a further seven subjects 
underwent elective repositioning during the trial to improve the contact of the 
array with the retina [74].
Overall, this is the largest and longest study of a retinal prosthesis system to 
date, demonstrating an acceptable safety profile and ongoing functionality and 
biocompatibility in the majority of subjects. Subsequent case series have shown 
improved safety profiles in parallel with growing surgical familiarity.
4.4 Functional outcomes
4.4.1 Visual function
There were three objective assessments used to evaluate visual function in the 
study. Firstly, a ‘square localization’ task, which involved the subject locating a 
white square displayed on a black background, indicated by touching the monitor. 
At 1 year, 94% of subjects could perform the task better with the device on than 
off. This was maintained at 3 years (89%) and 5 years (80.9%). The second task 
was ‘direction of motion’, which was assessed by asking the subject to indicate the 
direction of a high-contrast white line as it moved across the monitor. Initially 
57% of subjects performed better than chance with the device on, which was once 
again maintained at 3 and 5 years (56 and 50%), respectively. Of note, these two 
tests of visual function were not performed in all subjects at the 1-year time point, 
due to their introduction partway through the study. Finally visual function was 
assessed using, ‘grating visual acuity’, which consisted of randomly generated 
widths of black and white gratings in one of four different orientations, displayed 
for 5 s on a screen. Throughout the study, 27–48% of patients scored better than 
2.9 logMAR equivalent (mean 2.5 logMAR), depending on time point, with 38% 
performing significantly better with the device on than off at year 5. The best 
result recorded grating acuity was 1.8 logMAR, which approximates to a Snellen 
acuity of 20/1262 [57, 73–75]. The results from these tests of visual function are 
presented in Figure 5.
Dorn et al. tested the effect of providing scrambled spatial information to the 
device compared to one-to-one mapping, to investigate the degree to which the syn-
chronization of multiple electrode stimulation conferred a benefit during motion 
detection. They found that of the 15 subjects who were able to perform the initial 
motion detection task better with the device on, 10 (67%) also performed better 
with one-to-one mapping of spatial information, than with scrambled information 
[76]. This suggests that the pattern of phosphenes being elicited was important for 
motion detection, and not that the patient was using the device to detect light, and 
simply scanning with their head to determine direction.
Figure 5. 
Results for square localization (A), direction of motion (B) and grating visual acuity (C) at yearly time-points. 
Credit: da Cruz et al. [74].
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4.4.2 Orientation and mobility
In the phase II clinical trial, two tests of orientation and mobility were 
employed. The first involved locating a simulated black door on a white background 
across the room. The second consisted of the subject following a 6-inch-wide white 
line on the floor, either configured as a straight line, or with a 90° turn along its 
length. Successful performance was maintained at ~50 and 70% in each respec-
tive task with the device on, which was significantly better than 15–30% success 
with the device off [57, 73, 74]. Dagnelie et al. found a similar rate of performance 
success using a real world ‘sidewalk tracking’ test in 27 implanted subjects, showing 
that 67% performed above chance with the device on, compared to 22% with the 
system off [77]. Figure 6 illustrates the testing environments for orientation and 
mobility tasks.
4.4.3 Shape and object recognition
Arsiero et al. demonstrated, among implanted subjects, recognition of eight 
simple, solid, white shapes on a black background was significantly better the 
device on (31%) than off (13%), which improved further to 57% when the shapes 
were presented as outlines [79]. Luo et al. built upon this, presenting seven 
implanted subjects with eight high-contrast everyday items, both in the solid 
and outlined forms. It was found that subjects could identify solid objects to the 
same degree of accuracy with the device on as they could with the device on in the 
scrambled mode. Although superior to having the device off, this suggested that 
subjects were relying on visual cues other than the form presented but the array 
stimulation pattern. When the shapes were presented in their outlined forms, this 
significantly improved performance with the device on, above either that of the 
scrambled mode or with the device off [80].
Another real-world task described by Dagnelie et al., consisted of a ‘sock sort-
ing’ task, in which subjects were asked to sort a randomly arranged collection of 10 
black, 10 white and 10 grey socks into separate piles, according to colour. Each test 
was performed on a wooden table, or on a background of the subject’s choice (i.e. 
black or white). In both scenarios, the subjects performed significantly better on 
average with the device on than off [77].
4.4.4 Letter reading
In a study of 21 implanted subjects, da Cruz et al. studied functional form vision 
by assessing ability to discriminate high-contrast letters. Letters were grouped 
according to typographical complexity and randomly displayed on a computer 
Figure 6. 
Photographs of subjects performing door finding (A), line tracking (B) and sidewalk tracking (C) tasks. Credit: 
Humayun et al. [78], Dagnelie et al. [77].
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screen. Measurements from all subjects revealed a correct identification of 72% 
of group A (least complex) letters, presented at 30 cm, such that they subtended a 
visual angle of 41.27°. In the study, 19 and 20 subjects respectively completed the 
group B and group C letters, correctly identifying 55 and 52% in each instance. In 
all cases, performance was significantly better with the device turned on than off. 
A subset of six subjects who identified more than 50% of group A letters in fewer 
than 60 s went on to complete tests to assess the minimum letter size that could 
be resolved, while four of these six subjects were also assessed for performance on 
2-, 3- and 4-letter word identification. The minimum letter size correctly identi-
fied was 0.9 cm, subtending a visual angle of 1.7°. On average, four subjects could 
identify 6.8 out of 10 words, ranging from 11 to 20 cm in height. In all cases, the 
performance was significantly better when the device was switched on in standard 
mode, than when scrambled or off [81]. These results are very promising for the 
capacity of some patients to achieve good spatial resolution, approaching the 
theoretical limit of the system.
4.4.5 Prehension tasks
In a series of experiments using a 3D motion-capture system, Luo et al. measured 
the ability of five subjects to grasp a white block on a black table (Figure 7). With 
the device turned on, subjects would successfully initiate and complete a grasping 
action 74% of the time, compared to 0% with the device off [82, 83]. Unlike other 
object recognition tasks, this study suggests a good capacity for the system to permit 
performance of hand-eye coordination tasks in a 3D environment, similar to that of 
the real-world.
4.5 Patient-reported outcomes
An important consideration in visual restoration is the extent to which the 
recipients judge the system to be beneficial in everyday life. The Functional Low-
vision Observer Rated Assessment (FLORA) was developed by Geruschat et al. in 
order to evaluate the impact of partial restoration of ultra-low vision in subjects 
undergoing Argus II implantation. Initial results using the FLORA tool demon-
strated that it was able to provide useful information about the everyday functional 
benefit of prosthesis-derived visual restoration, as well as identifying areas in 
which rehabilitation could be utilized to maximize subjective value. At 1 year, the 
assessment demonstrated an 80% reported positive effect, which dropped to 65% at 
3 years. No patients reported a negative effect using this self-reporting tool [84, 85].
Figure 7. 
Subject performing prehension task (a) with live infrared motion capture of subject’s hand (b). Credit: Luo 
et al. [82].
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5. Future directions
There are several other groups across the world using a variety of techniques 
to develop retinal prosthetic systems. Currently the intelligent retinal implant 
system (IRIS) II (Pixium Vision S.A. France) is the only other epiretinal device 
that has received CE approval. The external components and power induction 
mechanism of this system are fairly similar to the Argus II system. However, 
unlike the Argus II system, the 150-microelectrode array receives stimula-
tion commands directly from an infrared array, which is integrated into a 
glasses-mounted visual interface, thus facilitating high data transfer and device 
miniaturization [45]. While initial data from the clinical trial were promising 
for functional and safety outcomes with the IRIS II, the study was postponed 
following concerns about device longevity [86].
The aforementioned Alpha IMS and its successor, the Alpha AMS (Retina 
Implant AG, Germany), have both been approved for commercial use in Europe. 
Utilizing photovoltaic technology, the Alpha IMS has 1500 autonomous photodiode 
complexes, giving a higher theoretical resolution than the Argus II. To date, this 
system has yielded safety and functional results similar to the Argus II, albeit with 
inferior longevity, possibly due to the surgical approach, involving subretinal 
device placement and a tunnelled link to a postauricular coil for electromagnetic 
power induction [35, 36, 87]. Preliminary data from trials of the Alpha AMS report 
considerable improvements in the lifespan of this system.
Finally, the Photovoltaic Retinal Implant (PRIMA) bionic vision system (also 
Pixium Vision S.A.) is currently undergoing a safety and performance evaluation 
feasibility study [88]. This subretinal system comprises a modular array set-up 
with 1 mm-wide hexagonal chips, each containing 142 30 μm-thick pixel cells, 
each ~70 μm2, which receive visual data from a visual interface as pulsed near 
infrared light. Multiple photodiodes in series are stimulated, generating sufficient 
current to polarize the adjacent neuronal tissue with a local concentric return to 
limit signal diffusion. This system is unique in that it is scalable through insertion 
of additional chips and does not require any direct transscleral delivery of power 
or data [37, 89, 90].
Several other groups are also investigating alternative methods of neural stimu-
lation, including optic nerve, cortical and thalamic prostheses [91]. As increasing 
numbers of patient volunteers undergo implantation with these systems, more data 
will become available, thus guiding the optimal design characteristics for future 
generations of devices.
Advancements in visually restorative medicine are not limited to prosthetics, 
with other regenerative technologies, including stem cells, gene therapy and opto-
genetics, demonstrating exciting developments in the endeavor to treat blindness 
[92–97]. In particular, optogenetics, an approach that is focused on targeting micro-
bial opsin (light-dependent ion channels) to surviving retinal neurons to rescue 
or restore visual function, has shown exciting results in in vivo animal and in vitro 
human studies [98–100]. In addition to the aforementioned organic approaches, 
these techniques are attractive insofar as they offer a biocompatible, autonomous 
and scalable alternative to inorganic systems, which could be administered earlier 
in the disease course as a rescue therapy. It is widely anticipated that these strategies 
will soon build on the initial success of synthetic prosthetics, or potentially comple-
ment them in the form of biohybrid implants.
The success of the Argus II is representative of the enormous progress that has 
been made in the field of retinal prosthetics over the past 3 decades. However, there 
remain significant challenges to be overcome before the concept of ‘bionic vision’ is 
fully realized. Despite this, retinal prostheses have delivered the most compelling 
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